[go: up one dir, main page]

BRPI0509150A - compostos para a inibição de angiogênese e uso destes - Google Patents

compostos para a inibição de angiogênese e uso destes

Info

Publication number
BRPI0509150A
BRPI0509150A BRPI0509150-0A BRPI0509150A BRPI0509150A BR PI0509150 A BRPI0509150 A BR PI0509150A BR PI0509150 A BRPI0509150 A BR PI0509150A BR PI0509150 A BRPI0509150 A BR PI0509150A
Authority
BR
Brazil
Prior art keywords
compounds
inhibiting angiogenesis
angiogenesis
inhibition
viii
Prior art date
Application number
BRPI0509150-0A
Other languages
English (en)
Inventor
Grit Zahn
Roland Stragies
Frank Osterkamp
Gunther Zischinsky
Gerd Hummel
Sascha Birkner
Ulrich Reineke
Original Assignee
Jerini Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jerini Ag filed Critical Jerini Ag
Publication of BRPI0509150A publication Critical patent/BRPI0509150A/pt
Publication of BRPI0509150B1 publication Critical patent/BRPI0509150B1/pt
Publication of BRPI0509150B8 publication Critical patent/BRPI0509150B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)

Abstract

COMPOSTOS PARA A INIBIçãO DE ANGIOGêNESE E USO DESTES. A presente invenção invenção refere-se aos compostos de estrutura (I). Particularmente esta invenção é direcionada aos compostos de estrutura (VIII) em que as variáveis são definidas como na descrição. Estes compostos são inibidores de integrina e são úteis no tratamento de doenças nas quais uma inibição de angiogênese é desejada.
BRPI0509150A 2004-03-24 2005-03-24 compostos para a inibição de angiogênese e uso destes BRPI0509150B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP04007067.4 2004-03-24
EP04007067 2004-03-24
PCT/EP2005/003163 WO2005090329A1 (en) 2004-03-24 2005-03-24 New compounds for the inhibition of angiogenesis and use of thereof

Publications (3)

Publication Number Publication Date
BRPI0509150A true BRPI0509150A (pt) 2007-08-28
BRPI0509150B1 BRPI0509150B1 (pt) 2020-12-01
BRPI0509150B8 BRPI0509150B8 (pt) 2021-05-25

Family

ID=34962519

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0509150A BRPI0509150B8 (pt) 2004-03-24 2005-03-24 compostos para a inibição de angiogênese e uso destes

Country Status (16)

Country Link
US (1) US8501787B2 (pt)
EP (1) EP1727811B1 (pt)
JP (1) JP5032299B2 (pt)
KR (1) KR101271375B1 (pt)
CN (1) CN1938293A (pt)
AU (1) AU2005223356B2 (pt)
BR (1) BRPI0509150B8 (pt)
CA (1) CA2560653C (pt)
ES (1) ES2530056T3 (pt)
MX (1) MXPA06010756A (pt)
PL (1) PL1727811T3 (pt)
PT (1) PT1727811E (pt)
RU (1) RU2393154C2 (pt)
SG (1) SG151303A1 (pt)
WO (1) WO2005090329A1 (pt)
ZA (1) ZA200606747B (pt)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR059224A1 (es) * 2006-01-31 2008-03-19 Jerini Ag Compuestos para la inhibicion de integrinas y uso de estas
TW200811164A (en) 2006-05-12 2008-03-01 Jerini Ag New heterocyclic compounds for the inhibition of integrins and use thereof
EP2027143A2 (en) 2006-05-23 2009-02-25 Irm Llc Compounds and compositions as channel activating protease inhibitors
US20080045521A1 (en) * 2006-06-09 2008-02-21 Astrazeneca Ab Phenylalanine derivatives
WO2008097676A1 (en) 2007-02-09 2008-08-14 Irm Llc Compounds and compositions as channel activating protease inhibitors
CN101951835B (zh) * 2007-12-05 2015-02-11 马维尔生物科学公司 纳米级对比剂和使用方法
US8980820B2 (en) 2009-01-19 2015-03-17 The Research Foundation For The State University Of New York Fatty acid binding proteins as drug targets for endocannabinoids
BR112013008452A2 (pt) * 2010-10-07 2016-06-28 Aerpio Therapeutics Inc composição e métodos de tratamento de edema ocular, neovascularização e doenças relacionadas
WO2013103317A1 (en) * 2012-01-05 2013-07-11 Clanotech Ab Quinoline compounds which are anti-angiogenic integrin alpha5 betal inhibitors for use in the treatment of fibrosis or fibrosis-related diseases
CA2940769A1 (en) 2014-02-25 2015-09-03 Achillion Pharmaceuticals, Inc. Amino compounds for treatment of complement mediated disorders
WO2015188107A1 (en) 2014-06-06 2015-12-10 Arizona Board of Regents of behalf of Arizona State University Unique self-assembled poly-amidoamine polymers and their electrochemical reactivity
WO2017035357A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Phosphonate compounds for treatment of medical disorders
WO2017035361A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Disubstituted compounds for the treatment of medical disorders
WO2017035401A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amide compounds for treatment of immune and inflammatory disorders
WO2017035351A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amino compounds for treatment of medical disorders
WO2017035405A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amino compounds for treatment of immune and inflammatory disorders
ES2908479T3 (es) 2015-08-26 2022-04-29 Achillion Pharmaceuticals Inc Compuestos para el tratamiento de trastornos inmunitarios e inflamatorios
AR105808A1 (es) 2015-08-26 2017-11-08 Achillion Pharmaceuticals Inc Compuestos de amida para el tratamiento de trastornos médicos
AR105809A1 (es) 2015-08-26 2017-11-08 Achillion Pharmaceuticals Inc Compuestos para el tratamiento de trastornos médicos
US10385097B2 (en) 2015-08-26 2019-08-20 Achillion Pharmaceuticals, Inc. Ether compounds for treatment of medical disorders
WO2017035409A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders
AR106018A1 (es) 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
WO2017035417A1 (en) * 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Phosphonate compounds for treatment of immune and inflammatory disorders
PL3985002T3 (pl) 2017-03-01 2025-09-15 Achillion Pharmaceuticals, Inc. Arylowe, heteroarylowe i heterocykliczne związki farmaceutyczne do leczenia zaburzeń medycznych
ES2933513T3 (es) 2017-03-01 2023-02-09 Achillion Pharmaceuticals Inc Compuestos macrocíclicos para el tratamiento de trastornos médicos
WO2018160891A1 (en) 2017-03-01 2018-09-07 Achillion Pharmaceutical, Inc. Pharmaceutical compounds for treatment of medical disorders
US20190038623A1 (en) 2017-08-02 2019-02-07 Achillion Pharmaceuticals, Inc. Therapeutic regimens for treatment of paroxysmal nocturnal hemoglobinuria
WO2020051532A2 (en) 2018-09-06 2020-03-12 Achillion Pharmaceuticals, Inc. Macrocyclic compounds for the treatment of medical disorders
WO2020051538A1 (en) 2018-09-06 2020-03-12 Achillion Pharmaceuticals, Inc. Morphic forms of complement factor d inhibitors
AU2019346464A1 (en) 2018-09-25 2021-04-08 Achillion Pharmaceuticals, Inc. Morphic forms of complement factor D inhibitors
CA3123583A1 (en) 2018-12-17 2020-06-25 Achillion Pharmaceuticals, Inc. Targeted dosing for the treatment of complement mediated disorders
KR20220004024A (ko) 2019-03-22 2022-01-11 아칠리온 파르마세우티칼스 인코포레이티드 보체 매개 장애의 치료를 위한 약제학적 조성물

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4212304A1 (de) * 1992-04-13 1993-10-14 Cassella Ag Asparaginsäurederivate, ihre Herstellung und Verwendung
NZ314207A (en) * 1992-09-28 2000-12-22 Vertex Pharma 1-(2-Oxoacetyl)-piperidine-2-carboxylic acid derivatives as multi drug resistant cancer cell sensitizers
US5936065A (en) * 1993-12-06 1999-08-10 Cytel Corporation CS-1 peptidomimetics, compositions and methods of using the same
BR9710434A (pt) 1996-05-01 1999-08-17 Ortho Pharma Corp Derivados de carboxiamida de pirrolidina piperidina e hexahidroazepina para o tratamento de desordens trombÄticas
ID26219A (id) * 1998-01-23 2000-12-07 Aventis Pharma Gmbh Turunan-turunan sulfonamida baru sebagai penghambat-penghambat resorpsi tulang dan adhesi tulang
US6685617B1 (en) * 1998-06-23 2004-02-03 Pharmacia & Upjohn Company Inhibitors of α4β1 mediated cell adhesion
TW591026B (en) 1998-06-23 2004-06-11 Upjohn Co Inhibitors of alpha4beta1 mediated cell adhesion
DE10028402A1 (de) 2000-06-13 2001-12-20 Merck Patent Gmbh Pyridin-2-yl-aminoalkycarbonylglycyl-beta-alanin und Derivate
CA2430978C (en) * 2000-12-28 2012-05-15 Daiichi Pharmaceutical Co., Ltd. Vla-4 inhibitors

Also Published As

Publication number Publication date
RU2006137367A (ru) 2008-05-10
PL1727811T3 (pl) 2015-04-30
ZA200606747B (en) 2007-12-27
WO2005090329A1 (en) 2005-09-29
CN1938293A (zh) 2007-03-28
BRPI0509150B1 (pt) 2020-12-01
US8501787B2 (en) 2013-08-06
MXPA06010756A (es) 2006-12-15
KR20060128010A (ko) 2006-12-13
JP2007530491A (ja) 2007-11-01
CA2560653A1 (en) 2005-09-29
EP1727811A1 (en) 2006-12-06
KR101271375B1 (ko) 2013-06-07
JP5032299B2 (ja) 2012-09-26
BRPI0509150B8 (pt) 2021-05-25
EP1727811B1 (en) 2014-11-12
WO2005090329A9 (en) 2007-02-01
US20070155712A1 (en) 2007-07-05
HK1097827A1 (zh) 2007-07-06
RU2393154C2 (ru) 2010-06-27
SG151303A1 (en) 2009-04-30
AU2005223356A1 (en) 2005-09-29
PT1727811E (pt) 2015-02-09
ES2530056T3 (es) 2015-02-26
AU2005223356B2 (en) 2012-05-17
CA2560653C (en) 2013-08-06

Similar Documents

Publication Publication Date Title
BRPI0509150A (pt) compostos para a inibição de angiogênese e uso destes
BR112015020650A2 (pt) inibidores de histona demetilases
GT200800184A (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevencion de diabetes.
ECSP088875A (es) Tienopirimidinas con actividad inhibidora de mnk1/mnk2 para composiciones farmacéuticas
NI201100166A (es) Derivados de benzofuranilo utilizados como inhibidores de glucoquinasa
CL2007003802A1 (es) Compuestos derivados de piperidina, inhibidores de la sintasa de acidos grasos; procedimiento de preparacion de dichos compuestos; y su uso para tratar la obesidad o el sobrepeso.
UY32072A (es) Tienopirimidinas para composiciones farmacéuticas
BRPI0815708A8 (pt) composto derivado de benzilbenzeno como inibidor de sglt, composição farmacêutica, e, uso de um composto
BRPI0712816B8 (pt) compostos de pirrolpirimidina e seus usos
BRPI0713349A2 (pt) Inibidores de proteína tirosina fosfatase humana e métodos de utilização
BRPI0617159B8 (pt) compostos de piridopirimidinone inibidores de pi3ka, composições que os contem e processo para preparo
CL2008002319A1 (es) Compuestos derivados de pirrolopirimidina; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer.
BR112013016595A2 (pt) inibidores de neprilisina
CO6382129A2 (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o provencion de diabetes
GT200800202A (es) Quinazolinas para la inhibicion de pdk1
CL2008000197A1 (es) Compuestos derivados de 2,4-diamino pirimidina, inhibidores de antranilamida de cinasa aurora; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer.
SV2009003307A (es) Quinazolinas para la inhibicion de pdk1
CR20120283A (es) Inhibidor de bromodominio de benzodiazepina
BRPI0720270B8 (pt) compostos 4-fenil-6-(2,2,2-triflúor-1-fenil etoxi) pirimidina, composição e forma de dosagem sólida
CL2008002775A1 (es) Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
CR20130024A (es) Compuestos heterocíclicos fusionados
CL2008002041A1 (es) Compuestos derivados de piperidina; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar ansiedad.
UY33246A (es) Tienopirimidinas que contienen cicloalquilo para composiciones farmacéuticas
CL2007002791A1 (es) Compuestos derivados de sulfonamida; composicion farmaceutica que comprende a estos compuestos; combinacion farmaceutica que comprende a estos compuestos; y su uso para tratar trastornos, enfermedades y afecciones seleccionadas de asma, broncoconstri
CL2008000029A1 (es) Compuestos derivados de 1-bencil imidazol, inhibidores de eg-5; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 01/12/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 24/03/2005 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B25D Requested change of name of applicant approved

Owner name: SHIRE ORPHAN THERAPIES GMBH (US)

B25A Requested transfer of rights approved

Owner name: TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP)

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 21A ANUIDADE.